Primary-source record
Summit announced initiation of global Phase 3 HARMONi-10 evaluating ivonescimab monotherapy versus durvalumab as consolidation therapy after concurrent chemoradiation in unresectable Stage III NSCLC. Primary endpoint is PFS. Site activations expected to begin in Q4 2026. This is Summit's sixth sponsored Phase 3 trial of ivonescimab.
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate Ivonescimab Versus Durvalumab as Consolidation Therapy Following Concurrent Chemoradiation Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC). The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Consolidation therapy, given after a patient has responded to initial treatment, aims to deepen or prolong that response and delay or prevent the cancer from coming back or progressing. HARMONi-10 is Summit’s sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC, following HARMONi, HARMONi-3, and HARMONi-7. The study extends Summit’s global clinical development pr
Summit Therapeutics to Present Ivonescimab Data Across 10 Abstracts at ESMO 2026
Summit Therapeutics opens Phase II SMT112-216 trial of ivonescimab regimens in 1L advanced ccRCC